Star Combo Pharma Ltd
ASX:S66
Intrinsic Value
Star Combo Pharma Ltd. engages in the manufacture and distribution of vitamis, dietary supplements, and skincare products. [ Read More ]
The intrinsic value of one S66 stock under the Base Case scenario is 0.127 AUD. Compared to the current market price of 0.145 AUD, Star Combo Pharma Ltd is Overvalued by 13%.
Valuation Backtest
Star Combo Pharma Ltd
Run backtest to discover the historical profit from buying and selling S66 stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Star Combo Pharma Ltd
Current Assets | 16.6m |
Cash & Short-Term Investments | 9.2m |
Receivables | 3.3m |
Other Current Assets | 4.2m |
Non-Current Assets | 24.3m |
PP&E | 22.9m |
Intangibles | 683.6k |
Other Non-Current Assets | 728.9k |
Current Liabilities | 2.9m |
Accounts Payable | 2.4m |
Accrued Liabilities | 334k |
Other Current Liabilities | 188.3k |
Non-Current Liabilities | 4.7m |
Long-Term Debt | 4m |
Other Non-Current Liabilities | 749.8k |
Earnings Waterfall
Star Combo Pharma Ltd
Revenue
|
25.7m
AUD
|
Cost of Revenue
|
-19.9m
AUD
|
Gross Profit
|
5.8m
AUD
|
Operating Expenses
|
-4.4m
AUD
|
Operating Income
|
1.4m
AUD
|
Other Expenses
|
-905.1k
AUD
|
Net Income
|
485.2k
AUD
|
Free Cash Flow Analysis
Star Combo Pharma Ltd
S66 Profitability Score
Profitability Due Diligence
Star Combo Pharma Ltd's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Score
Star Combo Pharma Ltd's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
S66 Solvency Score
Solvency Due Diligence
Star Combo Pharma Ltd's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Score
Star Combo Pharma Ltd's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
S66 Price Targets Summary
Star Combo Pharma Ltd
Shareholder Return
S66 Price
Star Combo Pharma Ltd
Average Annual Return | -31.01% |
Standard Deviation of Annual Returns | 7.77% |
Max Drawdown | -89% |
Market Capitalization | 19.6m AUD |
Shares Outstanding | 135 003 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Star Combo Pharma Ltd. engages in the manufacture and distribution of vitamis, dietary supplements, and skincare products. The company is headquartered in Sydney, New South Wales. The company went IPO on 2018-05-16. The firm develops, manufactures, and distributes a range of branded vitamins, dietary supplements, and skincare products, serving both domestic and offshore markets. The firm operates through two segments: Star Combo business and Austoyou retail. Star Combo business segment includes developing, manufacturing, marketing and sales of natural health supplements and skin care products. Austoyou retail business made up of the Australia-China e-commerce platform that offers products directly to Chinese health product consumers; and Koala Mall’s two retail stores in Sydney. Its products include Costar NMN, Costar osteo comples Gluco, Living Healthy and Little, Amax Top Marine Collagen E ,J&K Ultra nourishing colla and J&K Rose Oil Lanolin Cream. The company also provides Original Equipment Manufacturer (OEM) Services and Quality Assurance.
Contact
IPO
Employees
Officers
The intrinsic value of one S66 stock under the Base Case scenario is 0.127 AUD.
Compared to the current market price of 0.145 AUD, Star Combo Pharma Ltd is Overvalued by 13%.